Main Article Content
Natural killer (NK) cells mediated immune responses via cytotoxic activity, or secreting cytokines. The interaction of NK cells with dendritic cells (DCs) contributes to NK cell-mediated anti-tumor or anti-microbial responses. However, the cellular and molecular mechanisms for controlling DC-mediated NK cell cytotoxicity interaction are largely unknown. Here, we showed an involvement of Notch-1 signaling interaction in augmenting NK cell cytotoxicity mediated by DCs. Stimulation of DCs from 6 healthy donors with ipopolysaccharide (LPS) could induce Notch-1 receptor and enhance NK cell proliferation (64.71±1.89%) and their cytotoxicity activity (42.18±1.04%) against K562 cells (human erythroleukemic cell line). DC-mediated NK cell cytotoxicity was suppressed by Notch-1 inhibitor, a γ-secretase inhibitor, (11.91±0.62%), as compared to the LPS treated-DCs (p < 0.05, paired t-test). These results suggested a possible mechanism of DCs mediated NK cell expansion and cytotoxicity regarding to Notch-1 receptor, at least in part. These findings provided an insight that the modulation of Notch-1 signaling could be a strategy to eradicate tumors or to suppress NK cell-mediated diseases.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
2. Voss M, Bryceson YT. Natural killer cell biology illuminated by primary immunodefi ciency syndromes in humans. Clin Immunol 2017; 177: 29-42.
3. Law RH, Lukoyanova N, Voskoboinik I, Caradoc-Davies TT, Baran K, Dunstone MA, et al. The structural basis for membrane binding and pore formation by lymphocyte perforin. Nature 2010; 468(7322): 447-51.
4. Thomas R, Yang X. NK-DC crosstalk in immunity to microbial infection. J Immunol Res 2016; 2016: 6374379. (7 pages).
5. Mahmood S, Upreti D, Sow I, Amari A, Nandagopal S, Kung SK. Bidirectional interactions of NK cells and dendritic cells in immunotherapy: current and future perspective. Immunotherapy 2015; 7(3): 301-8.
6. Marcenaro E, Carlomagno S, Pesce S, Moretta A, Sivori S. NK/DC crosstalk in anti-viral response. Adv Exp Med Biol 2012; 946: 295-308.
7. Radtke F, Fasnacht N, Macdonald HR. Notch signaling in the immune system. Immunity 2010; 32(1): 14-27.
8. Cheng P, Zhou J, Gabrilovich D. Regulation of dendritic cell diff erentiation and function by Notch and Wnt pathways. Immunol Rev 2010; 234(1): 105-19.
9. Sauma D, Espejo P, Ramirez A, Fierro A, Rosemblatt M, Bono MR. Diff erential regulation of Notch ligands in dendritic cells upon interaction with T helper cells. Scand J Immunol 2011; 74(1): 62-70.
10. Wang YC, Hu XB, He F, Feng F, Wang L, Li W, et.al. Lipopolysaccharide-induced maturation of bone marrow-derived dendritic cells is regulated by notch signaling through the up-regulation of CXCR4. J Biol Chem 2009; 284(23): 15993-6003.
11. Qian XQ, Chen LL, Cheng Q, Tian Y, Luo XF, Wan XY. Inhibition of Notch 1 receptor infl uenced the diff erentiation of Lin-CD45RA-dendritic cell precursors within ovarian carcinoma microenvironment. BMC Immunol 2016; 17(1): 14. (9 pages).
12. Juillerat-Jeanneret L, Flohr A, Schneider M, Walter I, Wyss JC, Kumar R, et al. Targeted γ-secretase inhibition to control the Notch pathway in renal diseases. J Med Chem 2015; 58(20): 8097-109.
13. Kijima M, Yamaguchi T, Ishifune C, Maekawa Y, Koyanagi A, Yagita H, et al. Dendritic cell-mediated NK cell activation is controlled by Jagged2-Notch interaction. Proc Natl Acad Sci USA 2008; 105(19): 7010-5.
14. Felices M, Ankarlo DE, Lenvik TR, Nelson HH, Blazar BR, Verneris MR, et al. Notch signaling at later stages of Natural Killer cell development enhances KIR expression and functional maturation. J Immunol 2014; 193(7): 3344-54.
15. Tchekneva EE, Goruganthu MUL, Uzhachenko RV, Thomas PL, Antonucci A, Chekneva I, et al. Determinant roles of dendritic cell-expressed Notch Delta-like and Jagged ligands on anti-tumor T cell immunity. J Immunother Cancer 2019; 7(1): 95. (17 pages).
16. Zitvogel L, Terme M, Borg C, Trinchieri G. Dendritic cell-NK cell cross-talk: regulation and physiopathology. Curr Top Microbiol Immunol 2006; 298:157-74.
17. West WH, Cannon GB, Kay HD, Bonnard GD, Herberman RB. Natural cytotoxic reactivity of human lymphocytes against a myeloid cell line: characterization of eff ector cells. J Immunol 1977; 118(1): 355-61.
18. Li DY, Gu C, Min J, Chu ZH, Ou QJ. Maturation induction of human peripheral blood mononuclear cell-derived dendritic cells. Exp Ther Med 2012; 4(1): 131-4.
19. Sanchez-Martinez D, Allende-Vega N, Orecchioni S, Talarico G, Cornillon A, Vo DN, et al. Expansion of allogeneic NK cells with effi cient antibody-dependent cell cytotoxicity against multiple tumors. Theranostics 2018; 8(14): 3856-69.
20. Tario JD Jr, Muirhead KA, Pan D, Munson ME, Wallace PK. Tracking immune cell proliferation and cytotoxic potential using fl ow cytometry. Methods Mol Biol 2011; 699: 119-64.
21. Janghorban M, Xin L, Rosen JM, Zhang XH. Notch signaling as a regulator of the tumor immune response: to target or not to target? Front Immunol 2018; 9: 1649. (10 pages).
22. Auderset F, Schuster S, Fasnacht N, Coutaz M, Charmoy M, Koch U, et.al. Notch signaling regulates follicular helper T cell diff erentiation. J Immunol 2013; 191(5): 2344-50.
23. Laky K, Evans S, Perez-Diez A, Fowlkes BJ. Notch signaling regulates antigen sensitivity of naive CD4+ T cells by tuning co-stimulation. Immunity 2015; 42(1): 80-94.
24. Radtke F, MacDonald HR, Tacchini-Cottier F. Regulation of innate and adaptive immunity by Notch. Nat Rev Immunol 2013; 13(6): 427-37.
25. Tanigaki K, Honjo T. Regulation of lymphocyte development by Notch signaling. Nat Immunol 2007; 8(5): 451-6.
26. Caton ML, Smith-Raska MR, Reizis B. Notch-RBP-J signaling controls the homeostasis of CD8- dendritic cells in the spleen. J Exp Med 2007; 204(7): 1653-64.
27. Shang Y, Smith S, Hu X. Role of Notch signaling in regulating innate immunity and infl ammation in health and disease. Protein Cell 2016; 7(3): 159-74.
28. Tsao PN, Wei SC, Huang MT, Lee MC, Chou HC, Chen CY, et al. Lipopolysaccharide-induced Notch signaling activation through JNK-dependent pathway regulates infl ammatory response. J Biomed Sci 2011; 18(1): 56. (9 pages).
29. Ferlazzo G, Morandi B. Cross-Talks between natural killer cells and distinct subsets of dendritic cells. Front Immunol 2014; 5: 159. (7 pages).
30. Fessenden TB, Duong E, Spranger S. A team eff ort: natural killer cells on the fi rst leg of the tumor immunity relay race. J Immunother Cancer 2018; 6(1): 67. (3 pages).
31. Van Elssen CH, Oth T, Germeraad WT, Bos GM, Vanderlocht J. Natural killer cells: the secret weapon in dendritic cell vaccination strategies. Clin Cancer Res 2014; 20(5): 1095-103.
32. Bol KF, Schreibelt G, Rabold K, Wculek SK, Schwarze JK, Dzionek A, et al. The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. J Immunother Cancer 2019; 7(1): 109. (13 pages).
33. Nasi A, Bollampalli VP, Sun M, Chen Y, Amu S, Nylén S. Immunogenicity is preferentially induced in sparse dendritic cell cultures. Sci Rep 2017; 7: 43989. (12 pages).
34. Renrick AN, Dunbar ZT, Shanker A. Update on the current revolution in cancer immunotherapy. Immunotherapy 2019; 11(1): 15-20.
35. Amon L, Hatscher L, Heger L, Dudziak D, Lehmann CHK. Harnessing the complete repertoire of conventional dendritic cell functions for cancer immunotherapy. Pharmaceutics 2020; 12(7): 663. (80 pages).
36. Sierra RA, Thevenot P, Raber PL, Cui Y, Parsons C, Ochoa AC, et al. Rescue of Notch-1 signaling in antigen-specifi c CD8+T cells overcomes tumor-induced T-cell suppression and enhances immunotherapy in cancer. Cancer Immunol Res 2014; 2(8): 800-11.